Repare Therapeutics (RPTX) Price & Analysis

Compare

429 Followers

RPTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.89 - $4.29

Previous CloseN/A

Volume283.97K

Average Volume (3M)398.61K

Market Cap

$58.33M

Enterprise ValueN/A

Total Cash (Recent Filing)$152.79M

Total Debt (Recent Filing)$1.93M

Price to Earnings (P/E)―

Beta1.18

Next Earnings

Aug 06, 2025

EPS Estimate

-0.56

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.71

Shares Outstanding42,891,403

10 Day Avg. Volume189,868

30 Day Avg. Volume398,614

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)0.32

Price to Sales (P/S)0.00

P/FCF Ratio-0.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$5.00

Price Target Upside267.65% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Repare Therapeutics News

PremiumThe Fly

Repare Therapeutics reports Q1 EPS (71c) vs 30c last year

15d ago

RPTX

PremiumThe Fly

Repare Therapeutics expects cash to fund operations through 2027

15d ago

RPTX

PremiumCompany Announcements

Repare Therapeutics Advances Strategic Partnerships and Clinical Trials Amid Financial Updates

15d ago

RPTX

PremiumPre-Earnings

RPTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

18d ago

RPTX

PremiumCompany Announcements

Repare Therapeutics Out-Licenses Platforms to DCx Biotherapeutics

28d ago

RPTX

PremiumMarket News

Cathie Wood Snags Robinhood Stock (HOOD) and GitLab (GTLB) as Markets Slide

2M ago

GTLB

HOOD

PremiumCompany Announcements

Repare Therapeutics Announces Leadership Changes in 2025

2M ago

RPTX

PremiumThe Fly

Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds

2M ago

RPTX

See All RPTX News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical ProgressManagement emphasized the enrollment progress in the POLAR trial and the potential to combine with a 'full dose' of olaparib without 'meaningful deterioration' of safety and tolerability.

Financial StabilityRepare Therapeutics has a cash balance of $152.8 million, providing funding into late 2027.

Partnership And MonetizationRepare Therapeutics announced an agreement with DCx Biotherapeutics to outlicense their preclinical discovery engines in exchange for $4M cash and other incentives.

Bears Say

Clinical RisksRisks include negative data from trials, failure to advance candidates into later-stage trials, and inability to obtain regulatory approval.

Financial PerformanceRepare reported a Q1 net loss of $30MM.

Restructuring RisksThe leadership transition comes in the wake of a previously-announced restructuring that includes a 75% workforce reduction and other leadership departures.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

1.74% Insiders

0.19% Mutual Funds

61.79% Other Institutional Investors

36.09% Public Companies and Individual Investors

Detailed Ownership Overview >

RPTX FAQ

What was Repare Therapeutics Inc’s price range in the past 12 months?

Repare Therapeutics Inc lowest stock price was $0.89 and its highest was $4.29 in the past 12 months.

What is Repare Therapeutics Inc’s market cap?

Repare Therapeutics Inc’s market cap is $58.33M.

When is Repare Therapeutics Inc’s upcoming earnings report date?

Repare Therapeutics Inc’s upcoming earnings report date is Aug 06, 2025 which is in 69 days.

How were Repare Therapeutics Inc’s earnings last quarter?

Repare Therapeutics Inc released its earnings results on May 13, 2025. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.655 by -$0.055.

Is Repare Therapeutics Inc overvalued?

According to Wall Street analysts Repare Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Repare Therapeutics Inc pay dividends?

Repare Therapeutics Inc does not currently pay dividends.

What is Repare Therapeutics Inc’s EPS estimate?

Repare Therapeutics Inc’s EPS estimate is -0.56.

How many shares outstanding does Repare Therapeutics Inc have?

Repare Therapeutics Inc has 42,891,403 shares outstanding.

What happened to Repare Therapeutics Inc’s price movement after its last earnings report?

Repare Therapeutics Inc reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.655. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Repare Therapeutics Inc?

Currently, no hedge funds are holding shares in RPTX

Repare Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-71.64%

Trailing 12-Months

Asset Growth

-45.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Repare Therapeutics Inc

Repare Therapeutics (RPTX) is a precision oncology company focused on developing novel therapeutics by targeting specific vulnerabilities in cancer cells. The company leverages its proprietary SNIPRx platform to design and develop innovative treatments aimed at synthetic lethality, a process that targets cancer cells by exploiting genetic interactions. Repare's pipeline includes several candidates in clinical and preclinical stages, aimed at addressing unmet needs in cancer treatment.

RPTX Stock 12 Month Forecast

Average Price Target

$5.00

▲(267.65%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","1.5":"$1.5","4.5":"$4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.41,1.6861538461538461,1.962307692307692,2.2384615384615385,2.5146153846153845,2.7907692307692304,3.066923076923077,3.343076923076923,3.619230769230769,3.8953846153846152,4.171538461538462,4.447692307692307,4.723846153846154,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.41,1.6861538461538461,1.962307692307692,2.2384615384615385,2.5146153846153845,2.7907692307692304,3.066923076923077,3.343076923076923,3.619230769230769,3.8953846153846152,4.171538461538462,4.447692307692307,4.723846153846154,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.41,1.6861538461538461,1.962307692307692,2.2384615384615385,2.5146153846153845,2.7907692307692304,3.066923076923077,3.343076923076923,3.619230769230769,3.8953846153846152,4.171538461538462,4.447692307692307,4.723846153846154,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.7,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.33,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >